Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV

Vesicular Stomatitis Virus (VSV) is neuropathogenic in rodents but can be attenuated 50-fold by engineering the mouse interferon-beta (IFN-β) gene into its genome. Intravenously administered VSVs encoding IFN-β have potent activity against subcutaneous tumors in the 5TGM1 mouse myeloma model, withou...

Full description

Bibliographic Details
Main Authors:	Yarde, Danielle N., Naik, Shruthi, Nace, Rebecca A., Peng, Kah-Whye, Federspiel, Mark J., Russell, Stephen J.
Format:	Online
Language:	English
Published:	2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855306/

Similar Items

Curative one-shot systemic virotherapy in murine myeloma
by: Naik, Shruthi, et al.
Published: (2012)

Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy
by: Miller, Amber, et al.
Published: (2014)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
by: Naik, Shruthi, et al.
Published: (2012)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
by: Ayala Breton, Camilo, et al.
Published: (2015)

Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters
by: Bailey, Kent, et al.
Published: (2013)

ONCOLYTIC VIROTHERAPY
by: Russell, Stephen J, et al.
Published: (2012)

MicroRNA-Detargeted Mengovirus for Oncolytic Virotherapy
by: Ruiz, Autumn J., et al.
Published: (2016)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
by: Dold, Catherine, et al.
Published: (2016)

Meningeal involvement in multiple myeloma
by: Laribi, Kamel, et al.
Published: (2015)

Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
by: Thirukkumaran, Chandini M., et al.
Published: (2011)

Development and Applications of VSV Vectors Based on Cell Tropism
by: Tani, Hideki, et al.
Published: (2012)

Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes
by: Logan, Nicola, et al.
Published: (2016)

Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus
by: Liu, Yu-Ping, et al.
Published: (2011)

Evaluation of a replication-competent VSV-SIV vaccine candidate
by: Jurgens, CK, et al.
Published: (2012)

The effects of N-terminal insertion into VSV-G of an scFv peptide
by: Dreja, Hanna, et al.
Published: (2006)

Characterization of Monomeric Intermediates during VSV Glycoprotein Structural Transition
by: Albertini, Aurélie A., et al.
Published: (2012)

Cell- Cell Transmission of VSV-G Pseudotyped Lentivector Particles
by: Skinner, Amy M., et al.
Published: (2013)

VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9
by: Claudia Montagna, et al.
Published: (2018-09-01)

In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion
by: Wongthida, Phonphimon, et al.
Published: (2016)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
by: de Wit, Emmie, et al.
Published: (2015)

Analyses of Entry Mechanisms of Novel Emerging Viruses Using Pseudotype VSV System
by: Tani, Hideki
Published: (2014)

Progressive neurological deficits in multiple myeloma: meningeal myelomatosis without MRI abnormalities
by: van Ginkel, S., et al.
Published: (2011)

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy
by: Li, H, et al.
Published: (2013)

Pinhole Micro-SPECT/CT for Noninvasive Monitoring and Quantitation of Oncolytic Virus Dispersion and Percent Infection in Solid Tumors
by: Penheiter, Alan R., et al.
Published: (2011)

The use of the NIS reporter gene for optimizing oncolytic virotherapy
by: Miller, Amber, et al.
Published: (2016)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
by: Svetlana Balkanov, Krstevska, et al.
Published: (2014)

Multiple Myeloma with Cutaneous Deposits as Rare Lymphoplasmacytoid Cells
by: Minni, Khushboo A, et al.
Published: (2015)

Case of Tubercular Spinal Meningitis with Deposit of Tubercle in the Liver and Peritoneum
by: Wise, J.
Published: (1874)

A prognostic index for multiple myeloma.
by: Grignani, G., et al.
Published: (1996)

Efficient generation of vesicular stomatitis virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies
by: Logan, Nicola, et al.
Published: (2016)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
by: Tober, R, et al.
Published: (2012)

Oncolytic viruses: methods and protocols
by: Harrington, Kevin J
Published: (2013)

Oncolytic Viruses
by: Chen, Nanhai G., et al.
Published: (2012)

Directed Fusion of Mesenchymal Stem Cells with Cardiomyocytes via VSV-G Facilitates Stem Cell Programming
by: Kouris, Nicholas A., et al.
Published: (2012)

High scFv-receptor affinity does not enhance the antitumor activity of HER2 retargeted measles virus
by: Suksanpaisan, Lukkana, et al.
Published: (2014)

Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice
by: Bartee, Eric, et al.
Published: (2016)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
by: Kelly, Kevin R., et al.
Published: (2015)

Interferon-Induced Ifit2/ISG54 Protects Mice from Lethal VSV Neuropathogenesis
by: Fensterl, Volker, et al.
Published: (2012)

Reconstituted G protein-lipid vesicles from vesicular stomatitus virus and their inhition of VSV infection
by: Miller, DK
Published: (1980)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
by: Yuan, M, et al.
Published: (2012)